Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

Measurement of changes in health across locations is useful to compare and contrast changing epidemiological patterns against health system performance and identify specific needs for resource allocation in research, policy development, and programme decision making. Using the Global Burden of Diseases, Injuries, and Risk Factors Study 2016, we drew from two widely used summary measures to monitor such changes in population health: disability-adjusted life-years (DALYs) and healthy life expectancy (HALE). We used these measures to track trends and benchmark progress compared with expected trends on the basis of the Socio-demographic Index (SDI). We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2016 for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2016. We calculated DALYs by summing years of life lost and years of life lived with disability for each location, age group, sex, and year. We estimated HALE using age-specific death rates and years of life lived with disability per capita. We explored how DALYs and HALE differed from expected trends when compared with the SDI: the geometric mean of income per person, educational attainment in the population older than age 15 years, and total fertility rate. The highest globally observed HALE at birth for both women and men was in Singapore, at 75·2 years (95% uncertainty interval 71·9-78·6) for females and 72·0 years (68·8-75·1) for males. The lowest for females was in the Central African Republic (45·6 years [42·0-49·5]) and for males was in Lesotho (41·5 years [39·0-44·0]). From 1990 to 2016, global HALE increased by an average of 6·24 years (5·97-6·48) for both sexes combined. Global HALE increased by 6·04 years (5·74-6·27) for males and 6·49 years (6·08-6·77) for females, whereas HALE at age 65 years increased by 1·78 years (1·61-1·93) for males and 1·96 years (1·69-2·13) for females. Total global DALYs remained largely unchanged from 1990 to 2016 (-2·3% [-5·9 to 0·9]), with decreases in communicable, maternal, neonatal, and nutritional (CMNN) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). The exemplars, calculated as the five lowest ratios of observed to expected age-standardised DALY rates in 2016, were Nicaragua, Costa Rica, the Maldives, Peru, and Israel. The leading three causes of DALYs globally were ischaemic heart disease, cerebrovascular disease, and lower respiratory infections, comprising 16·1% of all DALYs. Total DALYs and age-standardised DALY rates due to most CMNN causes decreased from 1990 to 2016. Conversely, the total DALY burden rose for most NCDs; however, age-standardised DALY rates due to NCDs declined globally. At a global level, DALYs and HALE continue to show improvements. At the same time, we observe that many populations are facing growing functional health loss. Rising SDI was associated with increases in cumulative years of life lived with disability and decreases in CMNN DALYs offset by increased NCD DALYs. Relative compression of morbidity highlights the importance of continued health interventions, which has changed in most locations in pace with the gross domestic product per person, education, and family planning. The analysis of DALYs and HALE and their relationship to SDI represents a robust framework with which to benchmark location-specific health performance. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform health policies, health system improvement initiatives, targeted prevention efforts, and development assistance for health, including financial and research investments for all countries, regardless of their level of sociodemographic development. The presence of countries that substantially outperform others suggests the need for increased scrutiny for proven examples of best practices, which can help to extend gains, whereas the presence of underperforming countries suggests the need for devotion of extra attention to health systems that need more robust support. Bill & Melinda Gates Foundation.

GBD 2016 DALYs and HALE Collaborators 《-》

Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Healthy life expectancy (HALE) and disability-adjusted life-years (DALYs) provide summary measures of health across geographies and time that can inform assessments of epidemiological patterns and health system performance, help to prioritise investments in research and development, and monitor progress toward the Sustainable Development Goals (SDGs). We aimed to provide updated HALE and DALYs for geographies worldwide and evaluate how disease burden changes with development. We used results from the Global Burden of Diseases, Injuries, and Risk Factors Study 2015 (GBD 2015) for all-cause mortality, cause-specific mortality, and non-fatal disease burden to derive HALE and DALYs by sex for 195 countries and territories from 1990 to 2015. We calculated DALYs by summing years of life lost (YLLs) and years of life lived with disability (YLDs) for each geography, age group, sex, and year. We estimated HALE using the Sullivan method, which draws from age-specific death rates and YLDs per capita. We then assessed how observed levels of DALYs and HALE differed from expected trends calculated with the Socio-demographic Index (SDI), a composite indicator constructed from measures of income per capita, average years of schooling, and total fertility rate. Total global DALYs remained largely unchanged from 1990 to 2015, with decreases in communicable, neonatal, maternal, and nutritional (Group 1) disease DALYs offset by increased DALYs due to non-communicable diseases (NCDs). Much of this epidemiological transition was caused by changes in population growth and ageing, but it was accelerated by widespread improvements in SDI that also correlated strongly with the increasing importance of NCDs. Both total DALYs and age-standardised DALY rates due to most Group 1 causes significantly decreased by 2015, and although total burden climbed for the majority of NCDs, age-standardised DALY rates due to NCDs declined. Nonetheless, age-standardised DALY rates due to several high-burden NCDs (including osteoarthritis, drug use disorders, depression, diabetes, congenital birth defects, and skin, oral, and sense organ diseases) either increased or remained unchanged, leading to increases in their relative ranking in many geographies. From 2005 to 2015, HALE at birth increased by an average of 2·9 years (95% uncertainty interval 2·9-3·0) for men and 3·5 years (3·4-3·7) for women, while HALE at age 65 years improved by 0·85 years (0·78-0·92) and 1·2 years (1·1-1·3), respectively. Rising SDI was associated with consistently higher HALE and a somewhat smaller proportion of life spent with functional health loss; however, rising SDI was related to increases in total disability. Many countries and territories in central America and eastern sub-Saharan Africa had increasingly lower rates of disease burden than expected given their SDI. At the same time, a subset of geographies recorded a growing gap between observed and expected levels of DALYs, a trend driven mainly by rising burden due to war, interpersonal violence, and various NCDs. Health is improving globally, but this means more populations are spending more time with functional health loss, an absolute expansion of morbidity. The proportion of life spent in ill health decreases somewhat with increasing SDI, a relative compression of morbidity, which supports continued efforts to elevate personal income, improve education, and limit fertility. Our analysis of DALYs and HALE and their relationship to SDI represents a robust framework on which to benchmark geography-specific health performance and SDG progress. Country-specific drivers of disease burden, particularly for causes with higher-than-expected DALYs, should inform financial and research investments, prevention efforts, health policies, and health system improvement initiatives for all countries along the development continuum. Bill & Melinda Gates Foundation.

GBD 2015 DALYs and HALE Collaborators 《-》

Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

How long one lives, how many years of life are spent in good and poor health, and how the population's state of health and leading causes of disability change over time all have implications for policy, planning, and provision of services. We comparatively assessed the patterns and trends of healthy life expectancy (HALE), which quantifies the number of years of life expected to be lived in good health, and the complementary measure of disability-adjusted life-years (DALYs), a composite measure of disease burden capturing both premature mortality and prevalence and severity of ill health, for 359 diseases and injuries for 195 countries and territories over the past 28 years. We used data for age-specific mortality rates, years of life lost (YLLs) due to premature mortality, and years lived with disability (YLDs) from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 to calculate HALE and DALYs from 1990 to 2017. We calculated HALE using age-specific mortality rates and YLDs per capita for each location, age, sex, and year. We calculated DALYs for 359 causes as the sum of YLLs and YLDs. We assessed how observed HALE and DALYs differed by country and sex from expected trends based on Socio-demographic Index (SDI). We also analysed HALE by decomposing years of life gained into years spent in good health and in poor health, between 1990 and 2017, and extra years lived by females compared with males. Globally, from 1990 to 2017, life expectancy at birth increased by 7·4 years (95% uncertainty interval 7·1-7·8), from 65·6 years (65·3-65·8) in 1990 to 73·0 years (72·7-73·3) in 2017. The increase in years of life varied from 5·1 years (5·0-5·3) in high SDI countries to 12·0 years (11·3-12·8) in low SDI countries. Of the additional years of life expected at birth, 26·3% (20·1-33·1) were expected to be spent in poor health in high SDI countries compared with 11·7% (8·8-15·1) in low-middle SDI countries. HALE at birth increased by 6·3 years (5·9-6·7), from 57·0 years (54·6-59·1) in 1990 to 63·3 years (60·5-65·7) in 2017. The increase varied from 3·8 years (3·4-4·1) in high SDI countries to 10·5 years (9·8-11·2) in low SDI countries. Even larger variations in HALE than these were observed between countries, ranging from 1·0 year (0·4-1·7) in Saint Vincent and the Grenadines (62·4 years [59·9-64·7] in 1990 to 63·5 years [60·9-65·8] in 2017) to 23·7 years (21·9-25·6) in Eritrea (30·7 years [28·9-32·2] in 1990 to 54·4 years [51·5-57·1] in 2017). In most countries, the increase in HALE was smaller than the increase in overall life expectancy, indicating more years lived in poor health. In 180 of 195 countries and territories, females were expected to live longer than males in 2017, with extra years lived varying from 1·4 years (0·6-2·3) in Algeria to 11·9 years (10·9-12·9) in Ukraine. Of the extra years gained, the proportion spent in poor health varied largely across countries, with less than 20% of additional years spent in poor health in Bosnia and Herzegovina, Burundi, and Slovakia, whereas in Bahrain all the extra years were spent in poor health. In 2017, the highest estimate of HALE at birth was in Singapore for both females (75·8 years [72·4-78·7]) and males (72·6 years [69·8-75·0]) and the lowest estimates were in Central African Republic (47·0 years [43·7-50·2] for females and 42·8 years [40·1-45·6] for males). Globally, in 2017, the five leading causes of DALYs were neonatal disorders, ischaemic heart disease, stroke, lower respiratory infections, and chronic obstructive pulmonary disease. Between 1990 and 2017, age-standardised DALY rates decreased by 41·3% (38·8-43·5) for communicable diseases and by 49·8% (47·9-51·6) for neonatal disorders. For non-communicable diseases, global DALYs increased by 40·1% (36·8-43·0), although age-standardised DALY rates decreased by 18·1% (16·0-20·2). With increasing life expectancy in most countries, the question of whether the additional years of life gained are spent in good health or poor health has been increasingly relevant because of the potential policy implications, such as health-care provisions and extending retirement ages. In some locations, a large proportion of those additional years are spent in poor health. Large inequalities in HALE and disease burden exist across countries in different SDI quintiles and between sexes. The burden of disabling conditions has serious implications for health system planning and health-related expenditures. Despite the progress made in reducing the burden of communicable diseases and neonatal disorders in low SDI countries, the speed of this progress could be increased by scaling up proven interventions. The global trends among non-communicable diseases indicate that more effort is needed to maximise HALE, such as risk prevention and attention to upstream determinants of health. Bill & Melinda Gates Foundation.

GBD 2017 DALYs and HALE Collaborators 《-》

Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systema

Detailed, comprehensive, and timely reporting on population health by underlying causes of disability and premature death is crucial to understanding and responding to complex patterns of disease and injury burden over time and across age groups, sexes, and locations. The availability of disease burden estimates can promote evidence-based interventions that enable public health researchers, policy makers, and other professionals to implement strategies that can mitigate diseases. It can also facilitate more rigorous monitoring of progress towards national and international health targets, such as the Sustainable Development Goals. For three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has filled that need. A global network of collaborators contributed to the production of GBD 2021 by providing, reviewing, and analysing all available data. GBD estimates are updated routinely with additional data and refined analytical methods. GBD 2021 presents, for the first time, estimates of health loss due to the COVID-19 pandemic. The GBD 2021 disease and injury burden analysis estimated years lived with disability (YLDs), years of life lost (YLLs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries using 100 983 data sources. Data were extracted from vital registration systems, verbal autopsies, censuses, household surveys, disease-specific registries, health service contact data, and other sources. YLDs were calculated by multiplying cause-age-sex-location-year-specific prevalence of sequelae by their respective disability weights, for each disease and injury. YLLs were calculated by multiplying cause-age-sex-location-year-specific deaths by the standard life expectancy at the age that death occurred. DALYs were calculated by summing YLDs and YLLs. HALE estimates were produced using YLDs per capita and age-specific mortality rates by location, age, sex, year, and cause. 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws. Uncertainty was propagated at each step of the estimation process. Counts and age-standardised rates were calculated globally, for seven super-regions, 21 regions, 204 countries and territories (including 21 countries with subnational locations), and 811 subnational locations, from 1990 to 2021. Here we report data for 2010 to 2021 to highlight trends in disease burden over the past decade and through the first 2 years of the COVID-19 pandemic. Global DALYs increased from 2·63 billion (95% UI 2·44-2·85) in 2010 to 2·88 billion (2·64-3·15) in 2021 for all causes combined. Much of this increase in the number of DALYs was due to population growth and ageing, as indicated by a decrease in global age-standardised all-cause DALY rates of 14·2% (95% UI 10·7-17·3) between 2010 and 2019. Notably, however, this decrease in rates reversed during the first 2 years of the COVID-19 pandemic, with increases in global age-standardised all-cause DALY rates since 2019 of 4·1% (1·8-6·3) in 2020 and 7·2% (4·7-10·0) in 2021. In 2021, COVID-19 was the leading cause of DALYs globally (212·0 million [198·0-234·5] DALYs), followed by ischaemic heart disease (188·3 million [176·7-198·3]), neonatal disorders (186·3 million [162·3-214·9]), and stroke (160·4 million [148·0-171·7]). However, notable health gains were seen among other leading communicable, maternal, neonatal, and nutritional (CMNN) diseases. Globally between 2010 and 2021, the age-standardised DALY rates for HIV/AIDS decreased by 47·8% (43·3-51·7) and for diarrhoeal diseases decreased by 47·0% (39·9-52·9). Non-communicable diseases contributed 1·73 billion (95% UI 1·54-1·94) DALYs in 2021, with a decrease in age-standardised DALY rates since 2010 of 6·4% (95% UI 3·5-9·5). Between 2010 and 2021, among the 25 leading Level 3 causes, age-standardised DALY rates increased most substantially for anxiety disorders (16·7% [14·0-19·8]), depressive disorders (16·4% [11·9-21·3]), and diabetes (14·0% [10·0-17·4]). Age-standardised DALY rates due to injuries decreased globally by 24·0% (20·7-27·2) between 2010 and 2021, although improvements were not uniform across locations, ages, and sexes. Globally, HALE at birth improved slightly, from 61·3 years (58·6-63·6) in 2010 to 62·2 years (59·4-64·7) in 2021. However, despite this overall increase, HALE decreased by 2·2% (1·6-2·9) between 2019 and 2021. Putting the COVID-19 pandemic in the context of a mutually exclusive and collectively exhaustive list of causes of health loss is crucial to understanding its impact and ensuring that health funding and policy address needs at both local and global levels through cost-effective and evidence-based interventions. A global epidemiological transition remains underway. Our findings suggest that prioritising non-communicable disease prevention and treatment policies, as well as strengthening health systems, continues to be crucially important. The progress on reducing the burden of CMNN diseases must not stall; although global trends are improving, the burden of CMNN diseases remains unacceptably high. Evidence-based interventions will help save the lives of young children and mothers and improve the overall health and economic conditions of societies across the world. Governments and multilateral organisations should prioritise pandemic preparedness planning alongside efforts to reduce the burden of diseases and injuries that will strain resources in the coming decades. Bill & Melinda Gates Foundation.

GBD 2021 Diseases and Injuries Collaborators 《-》

Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition.

The Global Burden of Disease Study 2013 (GBD 2013) aims to bring together all available epidemiological data using a coherent measurement framework, standardised estimation methods, and transparent data sources to enable comparisons of health loss over time and across causes, age-sex groups, and countries. The GBD can be used to generate summary measures such as disability-adjusted life-years (DALYs) and healthy life expectancy (HALE) that make possible comparative assessments of broad epidemiological patterns across countries and time. These summary measures can also be used to quantify the component of variation in epidemiology that is related to sociodemographic development. We used the published GBD 2013 data for age-specific mortality, years of life lost due to premature mortality (YLLs), and years lived with disability (YLDs) to calculate DALYs and HALE for 1990, 1995, 2000, 2005, 2010, and 2013 for 188 countries. We calculated HALE using the Sullivan method; 95% uncertainty intervals (UIs) represent uncertainty in age-specific death rates and YLDs per person for each country, age, sex, and year. We estimated DALYs for 306 causes for each country as the sum of YLLs and YLDs; 95% UIs represent uncertainty in YLL and YLD rates. We quantified patterns of the epidemiological transition with a composite indicator of sociodemographic status, which we constructed from income per person, average years of schooling after age 15 years, and the total fertility rate and mean age of the population. We applied hierarchical regression to DALY rates by cause across countries to decompose variance related to the sociodemographic status variable, country, and time. Worldwide, from 1990 to 2013, life expectancy at birth rose by 6·2 years (95% UI 5·6-6·6), from 65·3 years (65·0-65·6) in 1990 to 71·5 years (71·0-71·9) in 2013, HALE at birth rose by 5·4 years (4·9-5·8), from 56·9 years (54·5-59·1) to 62·3 years (59·7-64·8), total DALYs fell by 3·6% (0·3-7·4), and age-standardised DALY rates per 100 000 people fell by 26·7% (24·6-29·1). For communicable, maternal, neonatal, and nutritional disorders, global DALY numbers, crude rates, and age-standardised rates have all declined between 1990 and 2013, whereas for non-communicable diseases, global DALYs have been increasing, DALY rates have remained nearly constant, and age-standardised DALY rates declined during the same period. From 2005 to 2013, the number of DALYs increased for most specific non-communicable diseases, including cardiovascular diseases and neoplasms, in addition to dengue, food-borne trematodes, and leishmaniasis; DALYs decreased for nearly all other causes. By 2013, the five leading causes of DALYs were ischaemic heart disease, lower respiratory infections, cerebrovascular disease, low back and neck pain, and road injuries. Sociodemographic status explained more than 50% of the variance between countries and over time for diarrhoea, lower respiratory infections, and other common infectious diseases; maternal disorders; neonatal disorders; nutritional deficiencies; other communicable, maternal, neonatal, and nutritional diseases; musculoskeletal disorders; and other non-communicable diseases. However, sociodemographic status explained less than 10% of the variance in DALY rates for cardiovascular diseases; chronic respiratory diseases; cirrhosis; diabetes, urogenital, blood, and endocrine diseases; unintentional injuries; and self-harm and interpersonal violence. Predictably, increased sociodemographic status was associated with a shift in burden from YLLs to YLDs, driven by declines in YLLs and increases in YLDs from musculoskeletal disorders, neurological disorders, and mental and substance use disorders. In most country-specific estimates, the increase in life expectancy was greater than that in HALE. Leading causes of DALYs are highly variable across countries. Global health is improving. Population growth and ageing have driven up numbers of DALYs, but crude rates have remained relatively constant, showing that progress in health does not mean fewer demands on health systems. The notion of an epidemiological transition--in which increasing sociodemographic status brings structured change in disease burden--is useful, but there is tremendous variation in burden of disease that is not associated with sociodemographic status. This further underscores the need for country-specific assessments of DALYs and HALE to appropriately inform health policy decisions and attendant actions. Bill & Melinda Gates Foundation.

GBD 2013 DALYs and HALE Collaborators ，Murray CJ ，Barber RM ，Foreman KJ ，Abbasoglu Ozgoren A ，Abd-Allah F ，Abera SF ，Aboyans V ，Abraham JP ，Abubakar I ，Abu-Raddad LJ ，Abu-Rmeileh NM ，Achoki T ，Ackerman IN ，Ademi Z ，Adou AK ，Adsuar JC ，Afshin A ，Agardh EE ，Alam SS ，Alasfoor D ，Albittar MI ，Alegretti MA ，Alemu ZA ，Alfonso-Cristancho R ，Alhabib S ，Ali R ，Alla F ，Allebeck P ，Almazroa MA ，Alsharif U ，Alvarez E ，Alvis-Guzman N ，Amare AT ，Ameh EA ，Amini H ，Ammar W ，Anderson HR ，Anderson BO ，Antonio CA ，Anwari P ，Arnlöv J ，Arsic Arsenijevic VS ，Artaman A ，Asghar RJ ，Assadi R ，Atkins LS ，Avila MA ，Awuah B ，Bachman VF ，Badawi A ，Bahit MC ，Balakrishnan K ，Banerjee A ，Barker-Collo SL ，Barquera S ，Barregard L ，Barrero LH ，Basu A ，Basu S ，Basulaiman MO ，Beardsley J ，Bedi N ，Beghi E ，Bekele T ，Bell ML ，Benjet C ，Bennett DA ，Bensenor IM ，Benzian H ，Bernabé E ，Bertozzi-Villa A ，Beyene TJ ，Bhala N ，Bhalla A ，Bhutta ZA ，Bienhoff K ，Bikbov B ，Biryukov S ，Blore JD ，Blosser CD ，Blyth FM ，Bohensky MA ，Bolliger IW ，Bora Başara B ，Bornstein NM ，Bose D ，Boufous S ，Bourne RR ，Boyers LN ，Brainin M ，Brayne CE ，Brazinova A ，Breitborde NJ ，Brenner H ，Briggs AD ，Brooks PM ，Brown JC ，Brugha TS ，Buchbinder R ，Buckle GC ，Budke CM ，Bulchis A ，Bulloch AG ，Campos-Nonato IR ，Carabin H ，Carapetis JR ，Cárdenas R ，Carpenter DO ，Caso V ，Castañeda-Orjuela CA ，Castro RE ，Catalá-López F ，Cavalleri F ，Çavlin A ，Chadha VK ，Chang JC ，Charlson FJ ，Chen H ，Chen W ，Chiang PP ，Chimed-Ochir O ，Chowdhury R ，Christensen H ，Christophi CA ，Cirillo M ，Coates MM ，Coffeng LE ，Coggeshall MS ，Colistro V ，Colquhoun SM ，Cooke GS ，Cooper C ，Cooper LT ，Coppola LM ，Cortinovis M ，Criqui MH ，Crump JA ，Cuevas-Nasu L ，Danawi H ，Dandona L ，Dandona R ，Dansereau E ，Dargan PI ，Davey G ，Davis A ，Davitoiu DV ，Dayama A ，De Leo D ，Degenhardt L ，Del Pozo-Cruz B ，Dellavalle RP ，Deribe K ，Derrett S ，Des Jarlais DC ，Dessalegn M ，Dharmaratne SD ，Dherani MK ，Diaz-Torné C ，Dicker D ，Ding EL ，Dokova K ，Dorsey ER ，Driscoll TR ，Duan L ，Duber HC ，Ebel BE ，Edmond KM ，Elshrek YM ，Endres M ，Ermakov SP ，Erskine HE ，Eshrati B ，Esteghamati A ，Estep K ，Faraon EJ ，Farzadfar F ，Fay DF ，Feigin VL ，Felson DT ，Fereshtehnejad SM ，Fernandes JG ，Ferrari AJ ，Fitzmaurice C ，Flaxman AD ，Fleming TD ，Foigt N ，Forouzanfar MH ，Fowkes FG ，Paleo UF ，Franklin RC ，Fürst T ，Gabbe B ，Gaffikin L ，Gankpé FG ，Geleijnse JM ，Gessner BD ，Gething P ，Gibney KB ，Giroud M ，Giussani G ，Gomez Dantes H ，Gona P ，González-Medina D ，Gosselin RA ，Gotay CC ，Goto A ，Gouda HN ，Graetz N ，Gugnani HC ，Gupta R ，Gupta R ，Gutiérrez RA ，Haagsma J ，Hafezi-Nejad N ，Hagan H ，Halasa YA ，Hamadeh RR ，Hamavid H ，Hammami M ，Hancock J ，Hankey GJ ，Hansen GM ，Hao Y ，Harb HL ，Haro JM ，Havmoeller R ，Hay SI ，Hay RJ ，Heredia-Pi IB ，Heuton KR ，Heydarpour P ，Higashi H ，Hijar M ，Hoek HW ，Hoffman HJ ，Hosgood HD ，Hossain M ，Hotez PJ ，Hoy DG ，Hsairi M ，Hu G ，Huang C ，Huang JJ ，Husseini A ，Huynh C ，Iannarone ML ，Iburg KM ，Innos K ，Inoue M ，Islami F ，Jacobsen KH ，Jarvis DL ，Jassal SK ，Jee SH ，Jeemon P ，Jensen PN ，Jha V ，Jiang G ，Jiang Y ，Jonas JB ，Juel K ，Kan H ，Karch A ，Karema CK ，Karimkhani C ，Karthikeyan G ，Kassebaum NJ ，Kaul A ，Kawakami N ，Kazanjan K ，Kemp AH ，Kengne AP ，Keren A ，Khader YS ，Khalifa SE ，Khan EA ，Khan G ，Khang YH ，Kieling C ，Kim D ，Kim S ，Kim Y ，Kinfu Y ，Kinge JM ，Kivipelto M ，Knibbs LD ，Knudsen AK ，Kokubo Y ，Kosen S ，Krishnaswami S ，Kuate Defo B ，Kucuk Bicer B ，Kuipers EJ ，Kulkarni C ，Kulkarni VS ，Kumar GA ，Kyu HH ，Lai T ，Lalloo R ，Lallukka T ，Lam H ，Lan Q ，Lansingh VC ，Larsson A ，Lawrynowicz AE ，Leasher JL ，Leigh J ，Leung R ，Levitz CE ，Li B ，Li Y ，Li Y ，Lim SS ，Lind M ，Lipshultz SE ，Liu S ，Liu Y ，Lloyd BK ，Lofgren KT ，Logroscino G ，Looker KJ ，Lortet-Tieulent J ，Lotufo PA ，Lozano R ，Lucas RM ，Lunevicius R ，Lyons RA ，Ma S ，Macintyre MF ，Mackay MT ，Majdan M ，Malekzadeh R ，Marcenes W ，Margolis DJ ，Margono C ，Marzan MB ，Masci JR ，Mashal MT ，Matzopoulos R ，Mayosi BM ，Mazorodze TT ，Mcgill NW ，Mcgrath JJ ，Mckee M ，Mclain A ，Meaney PA ，Medina C ，Mehndiratta MM ，Mekonnen W ，Melaku YA ，Meltzer M ，Memish ZA ，Mensah GA ，Meretoja A ，Mhimbira FA ，Micha R ，Miller TR ，Mills EJ ，Mitchell PB ，Mock CN ，Mohamed Ibrahim N ，Mohammad KA ，Mokdad AH ，Mola GL ，Monasta L ，Montañez Hernandez JC ，Montico M ，Montine TJ ，Mooney MD ，Moore AR ，Moradi-Lakeh M ，Moran AE ，Mori R ，Moschandreas J ，Moturi WN ，Moyer ML ，Mozaffarian D ，Msemburi WT ，Mueller UO ，Mukaigawara M ，Mullany EC ，Murdoch ME ，Murray J ，Murthy KS ，Naghavi M ，Naheed A ，Naidoo KS ，Naldi L ，Nand D ，Nangia V ，Narayan KM ，Nejjari C ，Neupane SP ，Newton CR ，Ng M ，Ngalesoni FN ，Nguyen G ，Nisar MI ，Nolte S ，Norheim OF ，Norman RE ，Norrving B ，Nyakarahuka L ，Oh IH ，Ohkubo T ，Ohno SL ，Olusanya BO ，Opio JN ，Ortblad K ，Ortiz A ，Pain AW ，Pandian JD ，Panelo CI ，Papachristou C ，Park EK ，Park JH ，Patten SB ，Patton GC ，Paul VK ，Pavlin BI ，Pearce N ，Pereira DM ，Perez-Padilla R ，Perez-Ruiz F ，Perico N ，Pervaiz A ，Pesudovs K ，Peterson CB ，Petzold M ，Phillips MR ，Phillips BK ，Phillips DE ，Piel FB ，Plass D ，Poenaru D ，Polinder S ，Pope D ，Popova S ，Poulton RG ，Pourmalek F ，Prabhakaran D ，Prasad NM ，Pullan RL ，Qato DM ，Quistberg DA ，Rafay A ，Rahimi K ，Rahman SU ，Raju M ，Rana SM ，Razavi H ，Reddy KS ，Refaat A ，Remuzzi G ，Resnikoff S ，Ribeiro AL ，Richardson L ，Richardus JH ，Roberts DA ，Rojas-Rueda D ，Ronfani L ，Roth GA ，Rothenbacher D ，Rothstein DH ，Rowley JT ，Roy N ，Ruhago GM ，Saeedi MY ，Saha S ，Sahraian MA ，Sampson UK ，Sanabria JR ，Sandar L ，Santos IS ，Satpathy M ，Sawhney M ，Scarborough P ，Schneider IJ ，Schöttker B ，Schumacher AE ，Schwebel DC ，Scott JG ，Seedat S ，Sepanlou SG ，Serina PT ，Servan-Mori EE ，Shackelford KA ，Shaheen A ，Shahraz S ，Shamah Levy T ，Shangguan S ，She J ，Sheikhbahaei S ，Shi P ，Shibuya K ，Shinohara Y ，Shiri R ，Shishani K ，Shiue I ，Shrime MG ，Sigfusdottir ID ，Silberberg DH ，Simard EP ，Sindi S ，Singh A ，Singh JA ，Singh L ，Skirbekk V ，Slepak EL ，Sliwa K ，Soneji S ，Søreide K ，Soshnikov S ，Sposato LA ，Sreeramareddy CT ，Stanaway JD ，Stathopoulou V ，Stein DJ ，Stein MB ，Steiner C ，Steiner TJ ，Stevens A ，Stewart A ，Stovner LJ ，Stroumpoulis K ，Sunguya BF ，Swaminathan S ，Swaroop M ，Sykes BL ，Tabb KM ，Takahashi K ，Tandon N ，Tanne D ，Tanner M ，Tavakkoli M ，Taylor HR ，Te Ao BJ ，Tediosi F ，Temesgen AM ，Templin T ，Ten Have M ，Tenkorang EY ，Terkawi AS ，Thomson B ，Thorne-Lyman AL ，Thrift AG ，Thurston GD ，Tillmann T ，Tonelli M ，Topouzis F ，Toyoshima H ，Traebert J ，Tran BX ，Trillini M ，Truelsen T ，Tsilimbaris M ，Tuzcu EM ，Uchendu US ，Ukwaja KN ，Undurraga EA ，Uzun SB ，Van Brakel WH ，Van De Vijver S ，van Gool CH ，Van Os J ，Vasankari TJ ，Venketasubramanian N ，Violante FS ，Vlassov VV ，Vollset SE ，Wagner GR ，Wagner J ，Waller SG ，Wan X ，Wang H ，Wang J ，Wang L ，Warouw TS ，Weichenthal S ，Weiderpass E ，Weintraub RG ，Wenzhi W ，Werdecker A ，Westerman R ，Whiteford HA ，Wilkinson JD ，Williams TN ，Wolfe CD ，Wolock TM ，Woolf AD ，Wulf S ，Wurtz B ，Xu G ，Yan LL ，Yano Y ，Ye P ，Yentür GK ，Yip P ，Yonemoto N ，Yoon SJ ，Younis MZ ，Yu C ，Zaki ME ，Zhao Y ，Zheng Y ，Zonies D ，Zou X ，Salomon JA ，Lopez AD ，Vos T ... -  《-》